Willow, InMed and BaymedicaWillow should join forces with InMed and Baymedica to counter Gingko InMed Announced LOI to Acquire BayMedica A leading rare cannabinoid manufacturer utilizing proprietary manufacturing techniques to produce rare, non-intoxicating, regulatory compliant, naturally-occurring cannabinoids Industry leading large-scale commercial production of CBC (cannabichromene) for B2B customers with current batch sizes in excess of 200kg; scalable to metric tonnes Revenue generating Strong revenue growth since first commercial sale in Q4 2019 Extensive, expanding patent portfolio in cannabinoid manufacturing and novel cannabinoid analogs Poised to launch several high-margin rare cannabinoids into the large and rapidly growing consumer health and wellness markets Has produced more than 20 natural cannabinoids using various manufacturing technologies including chemical synthesis and biosynthesis Extensive experience in drug discovery and pharmaceutical manufacturing